Sanara MedTech Q1 revenue up 26% to $23.4M; net loss widens to $3.5M

Sanara MedTech Inc.

2025-Q1 EPS reported -$0.41 revenue$23,434,096

Net revenue $23.4M (+26% YoY); net loss $3.5M vs $1.8M loss in Q1 2024.
Adjusted EBITDA improved to $0.7M from $0.3M; gross margin 92% vs 90%.
Sanara Surgical revenue drove growth; segment net loss $0.6M; Tissue Health Plus loss $2.9M.
Borrowed $12.25M under amended CRG term loan; $12.25M additional available through Dec 2025.
Appointed Elizabeth Taylor CFO; exclusive BMI license for OsStic bone void filler and ARC technology.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.